SymBiosis

Paradox Immunotherapeutics is thrilled to announce a $10 million investment from SymBiosis. The new funding will be used to accelerate the development of therapies for protein misfolding diseases, such as immunoglobulin light chain amyloidosis and leukocyte chemotactic factor 2 amyloidosis, and bring meaningful treatment to patients in need. The Paradox platform has already identified a promising pipeline of therapeutics, and we look forward to advancing our efforts with the support and partnership of Chidozie Ugwumba and the SymBiosis team. Read more about the news here: https://lnkd.in/g8ZfvP6K #biopharma #biotech #innovation #amyloidosis

We’re hiring! SymBiosis is expanding and looking for talented professionals to join our team in Bentonville, AR. We have six open positions across various functions—if you're passionate, driven, and ready to make an impact, we want to hear from you!   Open Positions: • Administrative Coordinator • Data Analyst • Fund Accountant • Investment Associate • Senior Data & Analytics Engineer • Vice President of Fund Operations Submit your application today and be a part of our dynamic team shaping the future of biotherapeutics innovations!   Learn more: https://lnkd.in/gmd_P8j3   #Hiring #VentureCapital #Investments #Bentonville

SymBiosis portfolio company Neurona Therapeutics has announced plans to initiate the pivotal Phase 3 EPIC trial of NRTX-1001, following alignment with the FDA under its Regenerative Medicine Advanced Therapy (RMAT) designation. The trial is expected to begin in 2H25.   The randomized, sham-controlled, double-blind study will evaluate NRTX-1001 in adults with drug-resistant mesial temporal lobe epilepsy.   In Phase 1/2 trials, NRTX-1001 achieved a 92% median reduction in disabling seizures (low-dose cohort), with no cognitive impairments observed.   Patients with drug-resistant epilepsy often face an extreme choice: undergoing brain surgery that removes or destroys brain tissue, risking cognitive impairment. NRTX-1001 could provide a new treatment option without the need for such an invasive procedure. Read more here: https://lnkd.in/g9UjRq_D     #VentureCapital #PortfolioCompany #Biotechnology

SymBiosis portfolio company AdvanCell has expanded its collaboration with Eli Lilly and Company to accelerate the development of novel Pb-212-based targeted alpha therapies for cancer treatment.   This expanded partnership leverages AdvanCell’s proprietary Pb-212 production technology and early-stage clinical infrastructure alongside Lilly’s expertise in oncology drug development. Together, they aim to drive forward an expanded pipeline of targeted alpha therapies, offering new hope for patients with hard-to-treat cancers.   As the field of radiopharmaceuticals continues to grow, this partnership marks a critical step in advancing innovative therapies that could redefine cancer treatment.   Learn more: https://lnkd.in/gFMJkj3s   #Biotechnology #Radiopharmaceuticals #PortfolioCompany

SymBiosis portfolio company eGenesis, Inc. has successfully transplanted a genetically engineered porcine kidney into a second patient at Massachusetts General Hospital as part of an FDA-authorized Expanded Access study. The patient has been discharged and is now off dialysis, marking progress toward expanding access to organ transplantation for those with end-stage kidney disease. eGenesis is developing human-compatible engineered organs through genetic modifications designed to improve compatibility and support long-term function. This latest success builds on the company’s progress in making xenotransplantation a viable solution for the thousands of patients in need of life-saving organ transplants. Read more here: https://lnkd.in/ekpYUgMP #Biotechnology #OrganTransplant #VentureCapital

We are proud to co-lead AdvanCell's oversubscribed $112 million Series C financing as they work to advance Pb-212-based targeted alpha therapies for cancer treatment. This funding will help AdvanCell expand its 40,000-square-foot manufacturing facility and capabilities, and progress its deep and developing pipeline of radionuclide-based cancer therapeutics. The company is currently enrolling patients in the highest dose cohort of its TheraPb Phase I/II clinical trial for ADVC001, a potentially best-in-class Pb-212-PSMA therapy being investigated for metastatic prostate cancer. The Series C funding represents a significant step in AdvanCell’s journey to become a global leader in radionuclide-based cancer therapeutics. Read more here: https://lnkd.in/gCsrKSQT #Biotechnology #PortfolioCompany #VentureCapital

SymBiosis congratulates portfolio company Metsera on pricing its IPO. The IPO is expected to generate approximately $275 million in gross proceeds, further supporting Metsera’s mission to advance innovative metabolic therapies.   Read more here: https://lnkd.in/gJEiZBeP   #Biotechnology #MetabolicHealth #PortfolioCompany

SymBiosis portfolio company Siolta Therapeutics has entered a joint research agreement with Cowellnex, a joint investment by Kirin and Kyowa Kirin, to develop a live biotherapeutic product (LBP) aimed at preventing necrotizing enterocolitis (NEC) in newborns. This collaboration brings together Siolta’s expertise in microbial science and Cowellnex’s institutional strength in gut microbiota research and pharmaceutical R&D. By leveraging Siolta’s Precision Symbiotics Platform™, the partnership aims to accelerate the development of targeted microbiome-based interventions that address NEC at its root cause. NEC remains a critical unmet medical need, and this partnership is a significant step forward in advancing microbiome-based therapies to improve neonatal care. Learn more: https://lnkd.in/gqnxkCiR #Biotechnology #Microbiome #PortfolioCompany

We are proud to support Metsera as they advance the next generation of metabolic treatments.   Metsera recently announced positive topline data from its Phase 2a clinical trial of MET-097i, an ultra-long acting, fully-biased GLP-1 receptor agonist (RA). In this 12-week study, MET-097i demonstrated up to 11.3% placebo-adjusted weight loss, with no plateau observed, reinforcing its potential as a once-monthly injectable treatment. Additionally, the study confirmed a strong tolerability profile and feasibility of switching from weekly to monthly dosing.   With these results, Metsera is accelerating late-stage clinical trials, aiming to reshape obesity and metabolic disease management with innovative, long-acting peptide therapies.   Read more here: https://lnkd.in/gBRXc-Qv   #Biotechnology #MetabolicHealth #VentureCapital

We are proud to continue our support of Metsera by participating in their $215 million Series B financing.    Metsera’s lead candidate, MET-097i, is an ultra-long acting, fully-biased injectable GLP-1 RA currently in Phase 2 trials. In early studies, MET-097i showed significant weight reduction potential, with a 7.5% weight loss from baseline and a 380-hour half-life, indicating the potential for once-monthly dosing.   In addition, Metsera has initiated trials for MET-233i, an ultra-long-acting amylin analog, and MET-002, an oral GLP-1 RA peptide. These programs leverage Metsera’s proprietary HALO™ lipidation and MOMENTUM™ oral delivery platforms to enhance therapeutic impact and patient convenience.   Metsera’s innovative approach is set to drive the next generation of metabolic treatments, addressing critical needs in weight management and metabolic health.   Read more here: https://lnkd.in/gbu5eqZg   #PortfolioCompany #Biotechnology #VentureCapital